LXEO

Over the past six months, Lexeo Therapeutics' stock (LXEO) experienced a decline of 20.90%, from $5.31 on September 22, 2025, to $4.20 on September 18, 2026, with a 52-week high of $10.99 and a low of $2.98. Key events included the acquisition of Mantle Therapeutics and new collaborations to expand its leadership in Friedreich's ataxia on September 22, 2026. On September 2, 2026, LXEO Q2 2026 earnings reflected a 3.2% EPS miss due to sustained R&D investment. A regulatory update for LX2006 was provided on June 15, 2026. An oral presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 was announced for October 1, 2026. Lexeo Therapeutics was scheduled to participate in the Chardan Healthcare Conference on October 8, 2026, and a 'Fireside Chat' event on October 20, 2026. A 12-month data update for LX2020 is expected in Q4 2026.